Impact of granulocytes on the antimicrobial effect of tedizolid in a mouse thigh infection model - Wikidata - awgldk - TriplyDB

Impact of granulocytes on the antimicrobial effect of tedizolid in a mouse thigh infection model

Impact of granulocytes on the antimicrobial effect of tedizolid in a mouse thigh infection model

http://www.wikidata.org/entity/Q35364245

about

Potential role of tedizolid phosphate in the treatment of acute bacterial skin infections New developments in the management of severe skin and deep skin structure infections - focus on tedizolid Tedizolid Phosphate: a Next-Generation Oxazolidinone.Pharmacokinetic drug evaluation of tedizolid for the treatment of skin infections.Broad-spectrum β-lactams in obese non-critically ill patients.Pharmacokinetics of tedizolid following oral administration: single and multiple dose, effect of food, and comparison of two solid forms of the prodrug Tedizolid population pharmacokinetics, exposure response, and target attainment.Novel approach to optimize synergistic carbapenem-aminoglycoside combinations against carbapenem-resistant Acinetobacter baumannii Profile of tedizolid phosphate and its potential in the treatment of acute bacterial skin and skin structure infections Comparative in vivo efficacies of epithelial lining fluid exposures of tedizolid, linezolid, and vancomycin for methicillin-resistant Staphylococcus aureus in a mouse pneumonia model.Comparative efficacies of human simulated exposures of tedizolid and linezolid against Staphylococcus aureus in the murine thigh infection model.Activity of tedizolid phosphate (TR-701) in murine models of infection with penicillin-resistant and penicillin-sensitive Streptococcus pneumoniae Comparative pharmacodynamics of the new oxazolidinone tedizolid phosphate and linezolid in a neutropenic murine Staphylococcus aureus pneumonia model Contribution of Oxazolidinones to the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse Model of Tuberculosis In Vitro and In Vivo Activities of a Bi-Aryl Oxazolidinone, RBx 11760, against Gram-Positive Bacteria.Optimization of Synergistic Combination Regimens against Carbapenem- and Aminoglycoside-Resistant Clinical Pseudomonas aeruginosa Isolates via Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling.Comparative In Vivo Efficacies of Tedizolid in Neutropenic versus Immunocompetent Murine Streptococcus pneumoniae Lung Infection Models.Antibiotics in development targeting protein synthesis.Use of pharmacokinetic/pharmacodynamic systems analyses to inform dose selection of tedizolid phosphate.Early experience with tedizolid: clinical efficacy, pharmacodynamics, and resistance.Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens.Tedizolid for treatment of acute bacterial skin and skin structure infections.Drug monitoring and individual dose optimization of antimicrobial drugs: oxazolidinones.Critical role of tedizolid in the treatment of acute bacterial skin and skin structure infections Pharmacokinetics/Pharmacodynamics of Peptide Deformylase Inhibitor GSK1322322 against Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus in Rodent Models of Infection.Polymyxin B in combination with doripenem against heteroresistant Acinetobacter baumannii: pharmacodynamics of new dosing strategies Comparative efficacies of tedizolid phosphate, vancomycin, and daptomycin in a rabbit model of methicillin-resistant Staphylococcus aureus endocarditis.How to solve the problem of spontaneous bacterial clearance when testing new antibiotic treatment: results on experimental pneumonia due to a derepressed cephalosporinase-producing Enterobacter cloacae.Dosing strategies to optimize currently available anti-MRSA treatment options (Part 2: PO options).Clinical Pharmacokinetics and Pharmacodynamics of Oxazolidinones.In vitro and in vivo activities of DS-2969b, a novel GyrB inhibitor, and its water-soluble prodrug, DS11960558, against methicillin-resistant Staphylococcus aureus.Translational Modeling of Antibacterial Agents

P2860

Q26853612-97A4A347-875F-42DF-AE2D-180E638CBA3B Q28083116-E2593F0E-6884-436B-9288-70FD808B6A49 Q33420646-FC943192-8EE7-4526-8B93-585AA6B4172D Q33438834-64BE2C1D-A990-4F7B-BB3F-E6E05F20A3B5 Q33839225-79C05610-8E10-447E-A031-44C95A281874 Q34548251-BEBBB317-8DCF-4D26-A38F-89A51E02B1D9 Q34596353-EAAC257E-B55F-4443-9DC5-A311CFB10E33 Q35168931-6316701D-D2B6-467B-94A8-5E869A3B79EA Q35542330-FF1FAFC3-F433-42E6-9811-7259823E7527 Q35941253-AE32EC93-9264-4F1A-B437-FCD6AA0860A2 Q36171683-8DC6D2BA-C743-4545-A414-F48C26D61E5E Q36172558-D525C129-7799-4593-AB8B-93CAF137D3CE Q36364009-A679CC9C-8FC9-4BB2-A5B8-B357D86C60A1 Q36439105-B8B8CA93-9F75-45E4-B64E-B0250A9C3796 Q37428616-660F5E67-8D44-4F7D-BE0F-BC169354FC53 Q37538623-1EC6DA68-DEA9-4048-A239-E9C613CDA789 Q37538738-C03FE122-A488-4E7C-AAFC-CBD8E69369BE Q37970724-FCFF9A22-28C9-485E-8331-C8FE5349BF1C Q38171760-849C7C39-ABA9-460A-B81F-B5092ED3951A Q38255366-E26C110C-C65A-4C86-8EF9-7B5CA10D834C Q38352171-6DA735CF-B8F6-4E60-A6B3-9357E30E2A4B Q38554583-3EF0FA48-2A0B-4C9C-87AC-EC290D5CAD42 Q38777085-B074A12F-85D5-4C2A-B081-73C13190898A Q39067666-2D0D1201-E7EB-42AA-A826-DE048B14DF71 Q40414549-CE50FC66-40E6-4D85-9D96-E475036B0E71 Q40587067-4515AAF6-CD6D-46AC-A972-4E2E75B76580 Q40675142-4FAAD60E-F867-4FB3-9D3A-C7FFB1FC50FA Q46243953-44968BDF-E656-4D7E-A195-355D9FF31486 Q47396324-B480D3B2-DA61-4489-B073-2193D19CA3AA Q47611899-7B0EB5DB-3BFC-4FA3-8BF0-3FDFEAEACBAE Q52611991-4F61B167-3992-4BD6-A73A-DC10DACDFF4C Q57240408-22EC590B-2E3E-4072-95DD-541300C0804F

P2860

Impact of granulocytes on the antimicrobial effect of tedizolid in a mouse thigh infection model

http://www.wikidata.org/entity/Q35364245

description

2011 nî lūn-bûn

@nan

2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Impact of granulocytes on the ...... a mouse thigh infection model

@ast

Impact of granulocytes on the ...... a mouse thigh infection model

@en

type

label

Impact of granulocytes on the ...... a mouse thigh infection model

@ast

Impact of granulocytes on the ...... a mouse thigh infection model

@en

prefLabel

Impact of granulocytes on the ...... a mouse thigh infection model

@ast

Impact of granulocytes on the ...... a mouse thigh infection model

@en

P1433

Q35364245-746A72A3-5F54-4E0F-8022-CD4DFE43C70D

P1476

Q35364245-F928188E-A0F5-4865-BC7F-A15C947F636C

P2093

Q35364245-20FD542E-E9DB-4987-877E-63924354A9A8

Q35364245-AC325676-0DEC-4AE9-8B61-9DF1321567D6

Q35364245-C614C9C7-B65D-438B-B9DE-F659829A9A6E

Q35364245-DB169710-2444-4638-8667-7F8F7048FB1E

P2860

Q35364245-2B1FA2D7-7BEE-4F96-B7EB-A3E2A88F420B

Q35364245-2E6C08D4-79EB-40E6-B34B-F73898602174

Q35364245-8332D3A8-A3FA-4FB2-AFCD-DE78584B732C

Q35364245-A4C46F4B-CCF1-4BBC-BCE9-8ECC4709D55B

Q35364245-F03035AB-9920-48A6-BA69-639BCB7D8764

Q35364245-F3F9BA9F-E305-45AF-984C-32E70CC1B4A3

Q35364245-FF892BF8-A380-4C4F-AF1F-8902BB5700C2

P304

Q35364245-B7E410EC-4D5E-424F-98B6-10694A7B50CB

P31

Q35364245-D779C3A5-B105-4B86-8BB7-BA6BCC8E1218

P356

Q35364245-6EC47870-D241-4DA2-B947-8285D769E0E0

P407

Q35364245-F57C2201-6C3F-4671-B491-EBFD9BC7A446

P433

Q35364245-3C341C9B-06A1-42D1-9FF1-252CDCD9781B

P478

Q35364245-60BB1DBC-4DFF-49A0-BB3A-A9FBBA24C620

P577

Q35364245-0CCC0710-6EA7-4F4E-AD06-209727AED121

P5875

Q35364245-9116A9D8-DEDA-40EB-AEDF-D7681646CE4F

P698

Q35364245-47208374-A574-4C82-9064-545D7566F06F

P932

Q35364245-FE9D2984-E9F6-4C9A-B6E9-A998E0B2C4CF

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Impact of granulocytes on the ...... a mouse thigh infection model

@en

P2093

Arnold Louie

http://www.w3.org/2001/XMLSchema#string

G L Drusano

http://www.w3.org/2001/XMLSchema#string

Robert Kulawy

http://www.w3.org/2001/XMLSchema#string

Weiguo Liu

http://www.w3.org/2001/XMLSchema#string

P2860

Impact of burden on granulocyte clearance of bacteria in a mouse thigh infection model

Pharmacodynamics of the new des-f(6)-quinolone garenoxacin in a murine thigh infection model.

Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections.

In vivo pharmacodynamics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains in a mouse thigh infection model.

In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection models

Cellular pharmacokinetics and intracellular activity of torezolid (TR-700): studies with human macrophage (THP-1) and endothelial (HUVEC) cell lines.

Antimicrobial Resistance: Pharmacokinetics‐Pharmacodynamics of Antimicrobial Therapy: It’s Not Just for Mice Anymore

P304

5300-5305

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.00502-11

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

55

http://www.w3.org/2001/XMLSchema#string

P577

2011-09-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51631930

http://www.w3.org/2001/XMLSchema#string

P698

21911576

http://www.w3.org/2001/XMLSchema#string

P932

3195040

http://www.w3.org/2001/XMLSchema#string